Trials / Completed
CompletedNCT06635408
Cystatin c: a Biomarker of AKI in Aneurysmal Subarachnoid Haemorrhage Patients
Cystatin c as a Predictive Biomarker of Acute Kidney Injury and Neurological Outcomes in Aneurysmal Subarachnoid Haemorrhage Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Alexandria University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The goal of this observational study is to assess cystatin c as a predictive biomarker of early acute kidney injury in aneurysmal subarachnoid hemorrhage patients. The main question it aims to answer is: \- Does cystatin c biomarker can predict early acute kidney injury in aneurysmal subarachnoid hemorrhage patients? Participants will be grouped into Aki and Non-Aki groups based on RIFLE criteria and Cystatin c biomarker will be tested to answer the study question.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | cystatin c | a biomarker to assess renal function |
Timeline
- Start date
- 2023-10-30
- Primary completion
- 2025-01-01
- Completion
- 2025-01-15
- First posted
- 2024-10-10
- Last updated
- 2025-04-24
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06635408. Inclusion in this directory is not an endorsement.